NCT07168486 is a Phase 1 clinical trial of CD19.20.22 CAR T cells in B-Cell Lymphoma, sponsored by University of Maryland, Baltimore.

Who is sponsoring NCT07168486?

NCT07168486 is sponsored by University of Maryland, Baltimore.

What drugs are being tested in NCT07168486?

Interventions in NCT07168486: CD19.20.22 CAR T cells, Fludarabine and Cyclophosphamide.

What condition does NCT07168486 study?

NCT07168486 studies B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma, Transformed Follicular Lymphoma (tFL), Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter Transformation, Marginal Zone Lymphoma.

Is NCT07168486 still recruiting?

NCT07168486 is currently enrolling by invitation. Last updated 11 September 2025.

Last reviewed 2025-09-11 · How we verify

NCT07168486

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

ENROLLING BY INVITATION Phase 1 Last updated 11 September 2025

What this trial tests

Phase 1 trial testing CD19.20.22 CAR T cells in B-Cell Lymphoma in 15 participants. Enrolling by invitation.

Timeline

28 October 2024

Primary endpoint
1 July 2027

1 July 2028

Quick facts

Lead sponsor	University of Maryland, Baltimore
Phase	Phase 1
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	28 October 2024
Primary completion	1 July 2027
Estimated completion	1 July 2028
Sites	1 location across United States

Drugs / interventions tested

CD19.20.22 CAR T cells — full drug profile →
Fludarabine and Cyclophosphamide — full drug profile →

Conditions studied

B-Cell Lymphoma — all drugs for B-Cell Lymphoma →
Diffuse Large B Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B Cell Lymphoma (DLBCL) →
Primary Mediastinal Large B-cell Lymphoma (PMBCL) — all drugs for Primary Mediastinal Large B-cell Lymphoma (PMBCL) →
Follicular Lymphoma — all drugs for Follicular Lymphoma →

Sponsor

University of Maryland, Baltimore

Who can join

18 and older, any sex, with B-Cell Lymphoma or Diffuse Large B Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to treat patients diagnosed with relapsed or refractory positive B cell lymphoma - positive for 2 or more target antigens - with CAR19.20.22 CAR T-cells. Based on the preclinical characteristics of the LTG2950, CAR19.20.22 tri-specific CAR T-cells the Investigators have developed the following hypotheses to be tested in our phase Ia clinical trial. The Investigators hypothesize that these novel CAR T-cells will show: * good safety and tolerability * a high degree of efficacy * very good persistence * an acceptable level of exhaustion

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Outcomes and salvage strategies for large B-cell lymphoma progressing after second-line CAR T-cell therapy: A DESCAR-T study from the LYSA group.
Sesques P, Manson G, Cartron G, Gros FX, et al · · 2026 · PMID 42099680 · DOI 10.1002/hem3.70356
Molecular Pathogenesis and Targeted Treatment of Richter Transformation
Maher N, Karami A, Matti B, Alwan A, et al · · 2026

Verify or expand the search:

Other recruiting trials for B-Cell Lymphoma

Currently open trials in the same condition.

NCT05615636 — A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL · Phase 2 · recruiting
NCT05757700 — Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma · Phase 1 · active not recruiting
NCT05442515 — CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory · Phase 1, PHASE2 · recruiting
NCT05092451 — Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C · Phase 1, PHASE2 · recruiting
NCT05281809 — Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia · Phase 2 · recruiting

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

NCT07537413 — Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia · Phase 4 · not yet recruiting
NCT07221799 — OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis · Phase 1 · not yet recruiting
NCT07094672 — Development of an Opioid Withdrawal Clinical Outcome Assessment · not yet recruiting
NCT06583239 — Hub-Based Engagement Navigator Service to Reduce CSC Disengagement · NA · not yet recruiting
NCT07536412 — Decision Aid Efficacy in Low Risk Thyroid Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07168486 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Maryland, Baltimore
Last refreshed: 11 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07168486.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing